News Desk, Amar Ujala, New Delhi
Updated Thu, 26 Nov 2020 10:29 PM IST
– Photo: Twitter
Hear the news
India is developing biotech ‘Kovaxin’ in association with Indian Council of Medical Research (ICMR). Sources said that Dr. Srivastava was given the first vaccine and in the next few days more than 15 thousand volunteers will be vaccinated in AIIMS.
A source said that the first dose of half a milliliter was given to the four volunteers through a needle. When contacted, Dr. Srivastava said that covaxin is the first anti-corona virus vaccine manufactured in the country and above that my institute is participating in the trial. As the first volunteer to be vaccinated, I feel proud. I am happy to be a part of this great cause. I am completely fine and working. Sources said that the second dose of 0.5 ml will be given 28 days after the first dose of 0.5 ml is given under test.
Under the third phase, 28,500 people aged 18 years and above will be vaccinated at various centers. The test will be done at around 25 centers in 10 states. Testing has also started in some places.
The Drug Controller of India (DCGI) has approved Bharat Biotech to conduct a third-stage human clinical trial of covaxin. Safety and immunogenicity data of the first and second phase trials have been made available to the central drug regulator.
The Hyderabad-based company, while applying for the third phase of testing, said that no serious side effects were reported on any volunteer regarding the vaccine. The source said that one of the common complaints was pain at the dipping site, which slowly faded away.
Apart from covaxin, four other vaccines in India are undergoing trials at different stages. The Serum Institute of India is testing the third phase of the Kovid-19 vaccine from Oxford-AstraZeneca, while the second phase of the country-made vaccine of Zydus-Cadila has been completed.